VI-RADS
Vesical Imaging Reporting and Data System
VI-RADS standardizes how bladder cancer is staged on multiparametric MRI, focused on the single question that changes management: has the tumor invaded the detrusor muscle? Using T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences, it assigns a 1-to-5 score for the likelihood of muscle invasion, helping distinguish non-muscle-invasive from muscle-invasive disease before transurethral resection. Low scores can support bladder-sparing decisions; higher scores flag the need for more aggressive staging. A neoadjuvant-specific adaptation (nacVI-RADS) extends it to response assessment after chemotherapy.
Version history & what changed
- VI-RADS v12018Current
The original consensus: a 1–5 score for detrusor-muscle-invasion likelihood on multiparametric MRI (T2, DWI, DCE), standardizing bladder-cancer staging before transurethral resection.
- nacVI-RADS (neoadjuvant adaptation)2020
A neoadjuvant-specific adaptation extending the score to response assessment after chemotherapy — a companion track rather than a replacement.
Latest on VI-RADS
No recent stories matched VI-RADS yet — check back soon.
Resources & links
- officialACR VI-RADS official page
RadPigeon is an independent radiology news digest and is not affiliated with or endorsed by International expert consensus (ACR steering committee). “VI-RADS” is a trademark of its owner and is named here only to refer to the system. Always consult the official source for the exact, current criteria.